COMPLETED

Telehealth Treatment for Opioid Use Disorders

Conditions

Opioid Use Disorder Harm Reduction Medication for Opioid Use Disorder

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study aims to use an Opioid Use Disorder (OUD) Telehealth Platform to reduce overdose events. This telehealth platform will be pilot tested to evaluate its preliminary efficacy in terms of motivating engagement in medications for OUD (MOUD), as well as its feasibility, acceptability and satisfaction to both first responders/providers and participants.

Official Title

A Pilot Study of Telehealth Treatment for Opioid Use Disorders

Quick Facts

Study Start:2024-05-01

Study Completion:2025-07-24

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:COMPLETED

Study ID

NCT05832879

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Can speak, read and write in English * Provision of signed and dated informed consent form * Have a history of at least one opioid overdose * Screened positive for OUD, moderate or severe, based on the Diagnostic and Statistical Manual-5th Edition * Have a working cell phone number and working device that can access a web browser and receive texts (i.e., smartphone, tablet or computer) OR be willing to use a device provided by the study team * Can provide a working email address OR be willing to create one	* Current use of buprenorphine, methadone, or naltrexone for a substance use disorder * Pregnancy or lactation * Known current suicide risk based on participant self-report * On parole or incarcerated at time of enrollment based on participant self-report

Inclusion Criteria

Exclusion Criteria

* Can speak, read and write in English
* Provision of signed and dated informed consent form
* Have a history of at least one opioid overdose
* Screened positive for OUD, moderate or severe, based on the Diagnostic and Statistical Manual-5th Edition
* Have a working cell phone number and working device that can access a web browser and receive texts (i.e., smartphone, tablet or computer) OR be willing to use a device provided by the study team
* Can provide a working email address OR be willing to create one

* Current use of buprenorphine, methadone, or naltrexone for a substance use disorder
* Pregnancy or lactation
* Known current suicide risk based on participant self-report
* On parole or incarcerated at time of enrollment based on participant self-report

Contacts and Locations

Principal Investigator

Rebekah Heckmann, MD, MPH, MPA

PRINCIPAL_INVESTIGATOR

Yale University

Study Locations (Sites)

Yale School of Medicine

New Haven, Connecticut, 06520

United States

Collaborators and Investigators

Sponsor: Yale University

Rebekah Heckmann, MD, MPH, MPA, PRINCIPAL_INVESTIGATOR, Yale University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-05-01

Study Completion Date2025-07-24

Study Record Updates

Study Start Date2024-05-01

Study Completion Date2025-07-24

Terms related to this study

Keywords Provided by Researchers

Harm Reduction
Medication for Opioid Use Disorder

Additional Relevant MeSH Terms

Opioid Use Disorder